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Abstract Colorectal cancer is an increasingly important
cause of death in Western countries. Endocannabinoids
inhibit colorectal carcinoma cell proliferation in vitro. In
this paper, we investigated the involvement of endocanna-
binoids on the formation of aberrant crypt foci (ACF,
earliest preneoplastic lesions) in the colon mouse in vivo.
ACF were induced by azoxymethane (AOM); fatty acid
amide hydrolase (FAAH) and cannabinoid receptor mes-
senger ribonucleic acid (mRNA) levels were analyzed by
the quantitative reverse transcription polymerase chain
reaction (RT-PCR); endocannabinoid levels were measured
by liquid chromatography–mass spectrometry; caspase-3
and caspase-9 expressions were measured by Western blot
analysis. Colonic ACF formation after AOM administration
was associated with increased levels of 2-arachidonoylglyc-
erol (with no changes in FAAH and cannabinoid receptor
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physiology of the digestive tract.mRNA levels) and reduction in cleaved caspase-3 and
caspase-9 expression. The FAAH inhibitor N-arachidonoyl-
serotonin increased colon endocannabinoid levels, reduced
ACF formation, and partially normalized cleaved caspase-3
(but not caspase-9) expression. Notably, N-arachidonoylser-
otonin completely prevented the formation of ACF with four
or more crypts, which have been show to be best correlated
with final tumor incidence. The effect of N-arachidonoylser-
otonin on ACF formation was mimicked by the cannabinoid
receptor agonist HU-210. No differences in ACF formation
were observed between CB1 receptor-deficient and wild-type
mice. It is concluded that pharmacological enhancement of
endocannabinoid levels (through inhibition of endocannabi-
noid hydrolysis) reduces the development of precancerous
lesions in the mouse colon. The protective effect appears to
involve caspase-3 (but not caspase-9) activation.
Keywords Aberrantcryptfoci.2-arachidonoylglycerol.
Cannabinoidreceptors.Coloncancer.Fattyacidamide
hydrolase(FAAH)
Abbreviations
AA-5-HT N-arachidonoylserotonin,
ACF aberrant crypt foci,
anandamide arachidonylethanolamide,
AOM azoxymethane,
2-AG 2-arachidonylglycerol,
DMSO dimethylsulfoxide;
FAAH fatty acid amide hydrolase,
HU-210 [(6aR)-trans-3-(1,1–dimethylheptyl)-
6a,7,10,10a-tetrahydro-1-hydroxy-6,6-di-
methyl-6H-dibenzo[b,d] pyran-9-methanol],
RT-PCR reverse transcription polymerase chain reac-
tion,
TRPV1 transient receptor potential vanilloid type 1
Introduction
Colon cancer remains a leading cause of death because of
cancer in the Western countries; the cumulative lifetime risk
of developing colorectal cancer is approximately 5–6% [1].
Development of colon cancer is a multistep process
involving a series of pathological alterations ranging from
discrete microscopic mucosal lesions, like aberrant crypt foci
(ACF), to malignant tumors [2]. ACF are early focal lesions
of the colonic mucosa composed of one to several enlarged
crypts, which are specifically induced by colon carcinogens
[3]. Easily identified in methylene blue-stained whole-mount
preparations under a dissecting microscope, ACF are used as
early indicators of colon carcinogenesis [1–3].
Cannabinoids have been licensed for clinical use as
palliative treatment of chemotherapy, but increasing evi-
dence shows antitumor actions of cannabinoid agonists on
several tumor cells in vitro and in animal models [4, 5]. The
main psychotropic cannabinoid is Δ
9-tetrahydrocannabinol,
which exerts its biological effects mainly by activating two
G protein-coupled cannabinoid receptors, named CB1 and
CB2 receptors [5]. Endogenous ligands for the cannabinoid
receptors have been identified; the best known are
arachidonylethanolamide (anandamide) and 2-arachido-
noylglycerol (2-AG) [4–6]. When released, anandamide
and 2-AG are removed from extracellular compartments by
a carrier-mediated reuptake process, and once within the
cell, both endocannabinoids are hydrolyzed by intracellular
hydrolytic enzymes of which the enzyme fatty acid amide
hydrolase (FAAH) is capable of recognizing both com-
pounds as substrates [5, 6].
The proposed mechanisms of the antitumoral effect of can-
nabinoids are complex and may involve induction of apo-
ptosis in tumor cells, antiproliferative actions, and an
antimetastatic effects through inhibition of angiogenesis and
tumorcellmigration[6]. Concerning the gastrointestinal tract,
it has been shown that cannabinoid receptor agonists, mostly
via CB1 activation, potently inhibit the cell proliferation of
colorectal carcinoma cell lines [7]. Furthermore, compounds
capable of inhibiting endocannabinoid degradation and hence
of prolonging the lifespan of endocannabinoids only when
and where these compounds are produced to exert physio-
logical or pathophysiological functions also inhibit colorectal
carcinoma growth in vitro [7]. Finally, in a study performed
on SW480 colon carcinoma cells, Joseph et al. [8] reported
that CB1 activation by anandamide inhibited tumor cell
migration, which is of paramount importance in metastasis
development. However, the potential antitumoral effect of
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logically manipulate endocannabinoid levels and action in
the gastrointestinal tract has never been explored in vivo.
Because CB1 receptor activation results in inhibition of
colorectal cell proliferation in vitro [7], we investigated here
the role of these receptors in the formation of ACF in vivo
by using CB1 receptor-deficient mice. In addition, in
pharmacological experiments, we also evaluated the effect
of drugs that are known to increase endocannabinoid levels
in the gastrointestinal tract (i.e., the FAAH inhibitor N-
arachidonoylserotonin [AA-5-HT] and the endocannabinoid
reuptake inhibitor VDM11 [(all Z) N-(2-methyl-3-hydroxy-
phenyl)-5,8,11,14-eicosa-tetraenamide]), as well as the effect
of the ultrapotent cannabinoid CB1/CB2 receptor agonist,
HU-210, on the formation of ACF in the mouse colon in
vivo. We also evaluated, by quantitative reverse transcription
polymerase chain reaction (RT-PCR), the degree of expres-
sion of the messenger ribonucleic acids (mRNAs) encoding
for the components of the endogenous cannabinoid system
(i.e., CB1 receptor, CB2 receptor, transient receptor potential
vanilloid type 1 [TRPV1], FAAH), which have been
implicated in cell proliferation and/or apoptosis [4–6].
Finally, because cannabinoids might exert antitumor actions
by counteracting caspase activation in tumor cells [4–6], we
evaluated the expression of caspase-3 and caspase-9 by
Western blot analysis. ACF were induced by the genotoxic
chemical azoxymethane (AOM) [9].
Materials and methods
Animals
Experiments were performed on female 5-week-old
C57BL/6N mice (Harlan Italy, Corezzana, MI; 20–22 g).
In some experiments, female mice lacking the CB1 receptor
gene, generated and genotyped as previously described
[10], were used. Mutant mice were in a mixed genetic
background with a predominance of C57BL/6N contribu-
tion (five backcrosses for both mutant lines). Mice were fed
ad libitum with standard mouse food, except for the
12-h period immediately preceding the killing of the
animals. All experiments complied with the Italian D.L.
no. 116 of 27 January 1992 and associated guidelines in the
European Communities Council Directive of 24 November
1986 (86/609/ECC).
Treatments
Mice were randomly divided into six groups as follows.
Group 1 was treated with vehicles; group 2 was treated with
AOM plus the vehicle used to dissolve cannabinoid drugs;
group 3 was treated with AOM plus the FAAH inhibitor
AA-5-HT (5 mg/kg); group 4 was treated with AOM plus
the anandamide transporter inhibitor VDM11 (5 mg/kg);
group 5 was treated with AOM plus the cannabinoid
receptor agonist HU210 ((6aR)-trans-3-(1,1-dimethylhep-
tyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-
dibenzo[b,d]pyran-9-methanol; 0.1 mg/kg). In another
series of experiments, AOM was given both to wild-type
and to CB1 deficient mice. AOM (16 mg/kg in total, IP)
was administered during the first (3 m/kg at days 1 and 5),
third (3 mg/kg at days 1 and 5), and at the 17th week (2 mg/
kg at days 1 and 5) of treatment.
Cannabinoid drugs were given intraperitoneally every
other day for the whole duration of the experiment (starting
from a week before the first injection of AOM). The doses
of cannabinoids were selected on the basis of previous
published work dealing with the effects of these drugs in
subchronic or chronic experiments [11–13].
All animals were euthanized by asphyxiation with CO2
6 months after the first injection of AOM. Based on our
laboratory experience, this time (at the dose of AOM used)
was associated with the occurrence of a significant number
of ACF.
Aberrant crypt foci technique
For ACF determination, the colons were rapidly removed
after killing, washed with saline, opened longitudinally, laid
flat on a polystyrene board, and fixed with 10% buffered
formaldehyde solution before being stained with 0.2%
methylene blue in saline. The colons were examined using
a light microscope at 40× magnification. Aberrant crypts
were identified as previously described [9]. Briefly, in
comparison to normal crypts, aberrant crypts have greater
size, larger and often elongated openings, thicker lining of
epithelial cells, compression of adjacent crypts, and are
more darkly stained with methylene blue. According to the
number of constituent crypt, ACF were divided into two
groups: small ACF containing one to three crypts per focus
and large ACF containing four or more crypts per focus. To
determine crypt multiplicity, the number of aberrant crypts
in each focus was recorded.
Identification and quantification of endocannabinoids
and palmitoylethanolamide
Full-thickness colons from control and AOM-treated mice
(in the presence or absence of AA-5-HT 5 mg/kg) were
removed (6 months after the first injection of AOM), and
tissue specimens were immediately weighed, immersed into
liquid nitrogen, and stored at −70°C until extraction of
endocannabinoids. Tissues were extracted with chloroform/
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d8-anandamide, d4-palmitoylethanolamide, and d5-2-AG,
synthesized as described previously (for the former two
compounds) [14], or provided by Cayman Chemicals (for
d5-2-AG, AnnArbor, MI). The lipid extracts were purified
by silica column chromatography and carried out as
described previously [14], and the fractions containing
anandamide, palmitoylethanolamide, and 2-AG were ana-
lyzed by isotope dilution liquid chromatography–atmospheric
pressure–chemicalionizationmassspectrometrycarriedoutin
the selected monitoring mode as described in detail elsewhere
[10, 14]. Results were expressed as picomoles or nanomoles
per milligram of extracted lipids.
Western blot analysis
Full-thickness colons from control and AOM-treated
(6 months after the first injection of AOM) mice (in the
presence or absence of AA-5-HT 5 mg/kg) were ho-
mogenized in lysis buffer (1:2 w/v) containing 0.5 M
β-glycerophosphate, 20 mM MgCl2, 10 mM ethylene glycol
tetraacetic acid, and supplemented with 100 mM dithio-
threitol and protease/phosphatase inhibitors (100 mM
dimethylsulfonyl fluoride, 2 mg/ml apronitin, 2 mM leu-
peptin, and 10 mM Na3VO4). Homogenates were centri-
fuged at 3,000 rpm for 5 min at 4°C; the supernatants were
collected and recentrifuged at 12,000 rpm for 10 min at 4°C.
Protein concentrations were determined using the method of
Bradford [15]. For Western blot analysis, lysate aliquots
containing 50 μg of proteins were denatured, separated on a
12% sodium dodecyl sulfate–polyacrylamide gel, and trans-
ferred to a nitrocellulose membrane (Amersham, Biosciences,
UK) using a Bio-Rad Transblot (350 mA for 3 h). Proteins
were visualized on the filters by reversible staining with
Ponceau-S solution (Sigma, Milan, Italy) and destained in
phosphate-buffered saline (PBS). Membranes were blocked
at 4°C in milk buffer (5% nonfat dry milk in PBS 1×/Tween
0.1%) and then incubated overnight at 4°C with polyclonal
antibodies for caspase-3 and caspase-9 (Calbiochem from
VWR International, Italy). The rabbit polyclonal anti-
caspase-3 and anti-caspase-9 were used at 1:1,000 dilution
in milk buffer (5% nonfat dry milk in PBS 1×/Tween 0.1%).
Subsequently, the membranes were incubated for 1 h at
room temperature with 1:2,000 anti-rabbit IgG–horseradish
peroxidase-conjugated secondary antibodies (Amersham
Biosciences, UK). After washing with PBS 1×/Tween
0.1%, the membranes were analyzed by enhanced chemilu-
minescence (Amersham Biosciences). The optical density of
the bands on autoradiographic films was determined by an
image analysis system (GS 700 Imaging Densitometer, Bio-
Rad) equipped with a software Molecular Analyst (IBM). After
stripping, the membranes were probed with anti-α-tubulin
antibody, to normalize the results.
Quantitative (real-time) RT PCR analysis
Full-thickness colons from control and AOM-treated
(6 months after the first injection of AOM) mice were
homogenized in 1 ml of Trizol® (Invitrogen). Total RNA
was extracted according to manufacturer recommendations,
dissolved in RNA storage solution (Ambion), UV quanti-
fied by a Bio-Photometer® (Eppendorf), and stored to −80°C.
RNA aliquots (6 μg) were digested by RNAse-free
DNAse I (Ambion deoxyribonucleic acid [DNA]-free™
kit) in a 20-μl final volume reaction mixture, to remove
contaminating genomic DNA. After DNAse digestion,
concentration and purity of RNA samples were evaluated
by the RNA-6000-Nano® microchip assay, using a 2100
Bioanalyzer® equipped with a 2100-Expert-Software®
(Agilent), following the manufacturer instructions. For all
samples tested, the RNA integrity number was greater than
6 (relatively to a 0–10 scale). Three micrograms of total
RNA, as evaluated by the 2100 Bioanalyzer, was reverse
t r a n s c r i b e di na2 5 - μl reaction mixture containing: 50 mM
Tris–HCl pH 8.3, 75 mM KCl, 3 mM MgCl2,1 0m M
dithiothreitol, 1 mM deoxyribonucleotide triphosphates,
20 U of RNAse inhibitor (Invitrogen), 0.125 A260 units of
hexanucleotide mixture (Invitrogen) for random priming
and 200 U of MoMuLV Superscript® III reverse transcrip-
tase (Invitrogen). The reaction mixture was incubated in a
termocycler iCycler-iQ® for a 5 min at a 55°C step,
followed by a rapid chilling for 2 min at 4°C. The protocol
was stopped at this step and the MoMuLV reverse
transcriptase was added to the samples, excepting the
negative controls (−RT). The incubation was resumed by
two thermal steps: 10 min at 20°C followed by 90 min at
50°C. Finally, the reaction was terminated by heating at 95°
C for 10 min. Quantitative real-time PCR was performed by
an iCycler-iQ® in a 25-μl reaction mixture containing:
1× iQ-SYBR®-Green-Supermix (Bio-Rad), 20 ng of com-
plementary DNA (cDNA; calculated on the basis of the
retro-transcribed RNA), and 330 nM for each primer. The
amplification profile consisted of an initial denaturation of
2 min at 94°C and 40 cycles of 30 s at 94°C, annealing for
30 s at optimum annealing temperature (TaOpt, see below)
and elongation for 45 s at 68°C. Fluorescence data were
collected during the elongation step. A final extension of
7 min was carried out at 72°C, followed by melt-curve data
analysis. Optimized primers for SYBR®-Green analysis
(and relative TaOpt) were designed by the Beacon-Designer®
software 6.0 version (Biosoft International, Palo Alto, CA)
and were synthesized (high-performance liquid chromatogra-
phy purification grade) by MWG-Biotech AG, Germany.
Assays were performed in quadruplicate (maximum ΔCt of
replicate samples less than 0.5), and a standard curve from
consecutive fivefold dilutions (100 to 0.16 ng) of a cDNA
pool representative of all samples was included, for PCR
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for PCR efficiency and normalized with respect to reference
genes β-actin and glyceraldehyde-3-phosphate dehydro-
genase (GADPH), was performed by GENEX software
(Bio-Rad) for groupwise comparison and statistical analysis.
Drugs
AOM and HU210 were purchased from Sigma and Tocris
Cookson (Bristol, UK), respectively. AA-5-HTand VDM11
were synthesized as described previously [16, 17]. All
drugs (with the exception of AOM, which was dissolved in
saline) were first dissolved in dimethylsulfoxide (DMSO)
and then suspended in a lipophilic solution (Peceol/
Gelucire 44/14, gift from Indena, Milan, Italy; 0.4%
DMSO, 96.6% lipophilic solution). The drug vehicle
(2.5 ml/kg) had no effect on the response under study.
Statistics
Data are expressed as the mean±SEM. To determine
statistical significance, analysis of varance followed by the
Dunnett’s (or Bonferroni’s for endocannabinoid levels) test
was used.
Results
Aberrant crypt foci formation
The total number of ACF/mouse and number of ACF/
mouse with four or more crypts observed after 6 months of
treatment with cannabinoid drugs in either the presence or
absence of AOM treatment are shown in Table 1. AOM
given alone induced the appearance of ACF in all the
animals. The average number of ACF for each mouse was
12.8±2.4 (0.57±0.20 ACF with four or more crypts). The
FAAH inhibitor AA-5-HT as well as the cannabinoid
receptor agonist HU210 significantly reduced the total
number of ACF/mouse and completely prevented the
formation of ACF with four or more crypts in all animals.
The anandamide reuptake inhibitor VDM11 showed a
nonsignificant trend at reducing the total number of ACF/
mouse and the number of ACF with four or more crypts.
Table 2 shows the result of experiments performed in
wild-type and CB1-deficient mice. In this series of experi-
ments, the total number of ACF/mouse and number of
ACF/mouse with four or more crypts did not change
significantly between the two groups of animals.
Endocannabinoid and palmitoylethanolamide content
in the colon
Endocannabinoid and palmitoylethanolamide content in
full-thickness colons of control and AOM-treated mice is
shown in Table 3. AOM treatment significantly increased
the levels of 2-AG and induced a nonsignificant trend to
increase the levels of anandamide and palmitoylethanola-
mide. The FAAH inhibitor AA-5-HT further increased
2-AG content and significantly increased anandamide (but
not palmitoylethanolamide) levels in AOM-treated mice. A
nonsignificant trend to increase anandamide levels was
observed also in AOM-treated mice treated with the
anandamide cellular reuptake inhibitor VDM11.
Evaluation of CB1,C B 2, FAAH, and TRPV1 mRNA levels
by quantitative RT-PCR
The relative expression analysis, evaluated by quantitative
RT-PCR, of CB1,C B 2, FAAH, and TRPV1 mRNA in full-
Table 1 Effect of cannabinoid drugs (arachidonoylserotonin [AA-5-
HT, 5 mg/kg], VDM11 [5 mg/kg], and HU210 [0.1 mg/kg]) on the
formation of aberrant crypt foci (ACF) induced in the mouse colon by
azoxymethane (AOM)
Treatment
(intraperitoneal)
Number of
ACF/mouse
Number of ACF/mouse
containing ≥4 crypts
Control 0 0
AOM 12.8±2.4 0.57±0.20
AOM+AA-5HT 6.3±1.4* 0*
AOM+VDM11 8.0±1.08 0.50±0.29
AOM+HU210 5.1±1.1* 0*
AOM (16 mg/kg in total, intraperitoneal) was administered during the
first (3 mg/kg at days 1 and 5), third (3 mg/kg at days 1 and 5), and at
the 17th week (2 mg/kg at days 1 and 5). Animals were euthanized
6 months after the first injection of AOM. Cannabinoid drugs were
given every other day for the whole duration of the experiment.
*p<0.05 vs AOM (n=6–9 mice for each experimental group)
Table 2 Induction of aberrant crypt foci (ACF) in wild-type and CB1-
deficient mice
Animal
type
Number of
ACF/mouse
Number of ACF/mouse
containing ≥4 crypts
Wild-type
mice
14.0±0.8 2.33±0.76
CB1-KO
mice
16.5±1.3 2.33±0.49
No significant differences were observed (n=6 for each experimental
group). Animals were euthanized 6 months after the first injection of
AOM. ACF were induced by AOM (16 mg/kg in total, intraperitoneal),
which was administered during the first (3 mg/kg at days 1 and 5),
third (3 mg/kg at days 1 and 5), and at the 17th week (2 mg/kg at
days 1 and 5)
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depicted in Fig. 1. All targets were well detectable in the
linearity range of analysis (CB1, mean cycle threshold=
26.5; CB2, mean cycle threshold=26; FAAH, mean cycle
threshold=18; TRPV1, mean cycle threshold=30; β-actin,
mean cycle threshold=16.5; GADPH, mean cycle threshold=
24.5). The amplification reaction efficiencies were compara-
ble, ranging from 96 to 108%. Colon samples showed
elevated expression (relatively to the other targets and to the
housekeeping genes) of FAAH, thus confirming the relevant
role of this enzyme in the digestive tract [18, 19], although no
variation of expression levels in colon samples from AOM-
treated mice and controls was observed. Likewise, no
variation of CB1 and CB2 expression levels was detected.
On the contrary, a significant decrease (about fourfold) of
TPRV1 expression was observed in colon samples of AOM-
treated mice.
Expression of activated caspase-3 and caspase-9 on colon
of AOM-treated mice
AOM significantly (p<0.001) reduced the cleavage of the
p34 precursor of caspases-3 into its p17 active fragment and
the p46 precursor of caspases-9 into its p34 active fragment
in full-thickness colons (Fig. 2a and b). Treatment with
AA-5-HT significantly reduced the effect of AOM on the
expression of the activated caspase-3 but not on the
expression of the activated caspases-9 (Fig. 2a and b).
Table 3 Levels of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide in the mouse colon in control and in azoxymethane (AOM)-
treated mice
Treatment anandamide (pmol/mg lipids) 2-arachidonoylglycerol (pmol/mg lipids) palmitoylethanolamide (pmol/mg lipids)
Control 0.9±0.2 119.8±20.1 3.1±0.5
AOM 1.6±0.3 198.2±29.2* 6.3±1.8
AOM+AA-5-HT 3.4±0.9**
,*** 310.9±53.3*
,**** 5.0±1.4
AOM+VDM11 3.0±0.9 216.0±80.7 4.9±2.2
Results are expressed as mean±SEM from four to eight animals. AOM (16 mg/kg in total, intraperitoneal) was administered during the first
(3 mg/kg at days 1 and 5), third (3 mg/kg at days 1 and 5), and at the 17th week (2 mg/kg at days 1 and 5). In some experiments, AOM-treated
mice were given the FAAH inhibitor arachidonoylserotonin (AA-5-HT) or the cellular reuptake inhibitor VDM11 (both at the dose of 5 mg/kg
every other day for 6 months). Assay was performed 6 months after the first injection of AOM.
*p<0.05 and **p<0.01 vs control; ***p<0.05 ****p<0.01 vs AOM
Fig. 1 RelativeexpressionanalysisofcannabinoidCB1 receptors (CB1),
cannabinoid CB2 receptors (CB2), fatty acid amide hydrolase (FAAH)
and transient receptor potential vanilloid type 1 (TRPV1)i nc o l o n so f
azoxymethane (AOM)-treated mice and controls (Ctr). The assay was
performed 6 months after the first injection of AOM. Total RNA
extracted from colons of AOM-treated mice and controls was subjected
to quantitative (real-time) RT-PCR analysis as described in the
“Materials and methods.” Data were analyzed by GENEX software
for groupwise comparisons and statistical analysis. The lowest expres-
sion value for each target was considered as 1. See “Results” for mean
cycle thresholds that are indicative of absolute abundance of each target
and indicate the following rank of expression in control colons: FAAH>
CB1=CB2>TRPV1. Double asterisk, p<0.02 vs AOM
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ACF are believed to be the earliest identifiable neoplastic
lesions in the colon carcinogenetic model [1–3, 20]. They
exhibit a number of molecular mutations in regulatory
genes consonant with the development of human colon
cancer, most notably in the ras oncogene and antigen-
presenting cell tumor suppressor gene [20]. In comparison
to normal crypts, ACF have greater size, larger and often
elongated openings, thicker lining of epithelial cells,
compression of adjacent crypts, and are more darkly stained
with methylene blue [1–3, 20]. Recent studies also suggest
that ACF are precursors of colon cancer in humans, and this
further stimulates the need to identify drugs that may
prevent their progression [1–3, 20]. Our findings indicate
that the blockade of endocannabinoid enzymatic degrada-
tion protects against ACF formation.
FAAH is a membrane-associated protein responsible of
the degradation of endocannabinoids anandamide and
2-AG [21]. Mice lacking FAAH are severely impaired in
theirabilitytodegradeanandamideand,whentreatedwiththis
endocannabinoid, exhibit an array of intense CB1-dependent
behavioral responses, including hypomotility, analgesia,
catalepsy, and hypothermia [22]. In the digestive tract,
FAAH inhibition results in reduction in intestinal motility
[23] and anti-inflammatory effects in vivo [12, 24]. Further-
more, FAAH knockout results in lower sensitivity to the
proinflammatory agent dinitrobenzene sulfonic acid (DNBS)
[12]. The anti-inflammatory role of FAAH is relevant in the
light of the observation that inflammation plays an important
role in colon carcinogenesis [25]. In this paper, we have
shown that a 6-month treatment with AA-5-HT, a selective
FAAH inhibitor, strongly reduces the formation of ACF in
the mouse colon and completely prevented the number of
ACF with crypt multiplicity of greater than or equal to 4. The
significant reduction in the number of ACF with four or
more crypts is relevant in the light of previous reports in
which larger crypts were found to be best correlated with
final tumor incidence [1–3, 20]. We believe that the effect of
AA-5-HT is due to FAAH inhibition and not to nonspecific
effects or interactions with cannabinoid receptors for the
following reasons: (1) AA-5-HT administration increased the
levels of anandamide and 2-AG in the colon of mice treated
with AOM, similar to that previously observed in the small
intestine of healthy mice after acute intraperitoneal adminis-
tration [23] or in the colon or DNBS-treated mice after
repeated intraperitoneal administration [24] with this com-
pound; (2) AA-5-HT displays little or no affinity for
cannabinoid receptors [16]; (3) AA-5-HT exerted protective
effects in the present study at a dose (5 mg/kg) previously
shown to be inactive in the “open field,”“ hot plate,” and
rectal hypothermia tests, which are predictive of CB1
activation in rodents [16]; (4) AA-5-HT was also previously
found to be ineffective against anandamide cellular reuptake
[16], a mechanism that, however, does not seem to be
involved in the control of ACF formation, as VDM11, a
selective inhibitor of anandamide cellular uptake, did not
significantly affect ACF formation in the present study. The
dose of VDM11 used in the present experiments was found
to enhance rat hippocampal and mouse brain endocannabinoid
levels and to exert neuroprotective effects when administered
(intraperitoneally) subchronically every other day (as in our
Fig. 2 Effect of the FAAH
inhibitor arachidonoylserotonin
(AA-5-HT) on cleaved caspase-3
(a) and cleaved caspase-9 (b)
expression in colon of mice
treated with azoxymethane
(AOM). The assay was per-
formed 6 months after the first
injection of AOM. A Relative
expression of cleaved caspases-
3 (active fragment p17) and
caspase-9 (active fragment p34)
was quantified by densitometric
scanning and normalized by α-
tubulin. B Representative West-
ern blot analysis. Data are
expressed as mean±SE of three
independent experiments. Num-
ber sign, p<0.001 vs control;
triple asterisk, p<0.001 vs
AOM
J Mol Med (2008) 86:89–98 95experimental conditions) [26]. Consistent with our results, it
was previously shown that chronic administration of
AA-5-HT (injected intratumor) inhibits the growth of
K-ras-transformed rat thyroid cells in athymic mice in vivo
[26]. More relevant to our present findings, AA-5-HT was
also previously shown to inhibit the proliferation of human
colorectal carcinoma cells in vitro in a way attenuated by CB1
receptor blockade, while increasing cell endocannabinoid
levels [7]. However, in these two previous studies and unlike
our present findings, VDM11 was also found to exert
antitumor effects both in vivo (albeit injected intratumor)
a n di nv i t r o .
The formation of ACF in mice after treatment with
AOM was associated per se to an increase in intestinal
2-AG levels, with a trend toward the increase in anandamide
levels too. It should be noted that we performed endocan-
nabinoid assay on full-thickness segments, and thus the cell
type responsible of 2-AG overproduction is presently
unknown. However, it is likely that these variations reflects
changes occurring in mucosal cells, as ACF are located on
the mucosa of the intestine [2, 3]. No changes were
observed, instead, in the expression of cannabinoid CB1
and CB2 receptors, as assessed by quantitative real-time
PCR. This finding is consistent with human studies, which
showed increased levels of endocannabinoids but not of
cannabinoid receptors, in the mucosa of colorectal adeno-
matous polyps and carcinomas [7]. It is likely that the
enhanced 2-AG levels in the gut exert protective effects on
colon carcinogenesis for the following reasons: (1) Phar-
macological blockade of endocannabinoid degradation and
subsequent elevation of both 2-AG and anandamide levels
results in a reduction in preneoplastic lesions (see above);
(2) anandamide and 2-AG potently inhibit the proliferation
of colorectal carcinoma cells [7]; (3) the protective effect of
AA-5-HT on ACF formation observed here was mimicked
by the synthetic cannabinoid receptor agonist HU210; we
used HU210 rather than endocannabinoids because of its
pharmacokinetic properties (i.e., longer half-life of HU210
as opposed to the high metabolic instability of both
anandamide and 2-AG). On these bases, we speculate that
the administration of AOM in animals increases 2-AG
levels, which, in turn, exerts protective effects. A likely
target of 2-AG is the cannabinoid CB2 receptor, whose
stimulation is known to exert proapoptotic effects [27, 28]
and to mediate antiproliferative effects on human colorectal
carcinoma cell lines [7]. It is unlikely that 2-AG could act
on cannabinoid CB1 receptors to mediate protective effects
because in the present study we have observed no statistical
differences in ACF formation between CB1-deficient and
wild-type mice. Others have found that systemic or local
treatment with cannabinoids inhibited the growth of various
types of tumor or tumor cell xenografts in vivo, including
lung carcinoma, glioma, thyroid epithelioma, lymphoma,
breast carcinoma, and skin carcinoma in mice, via both
CB1-a n dC B 2-mediated pathways as well as through non-
cannabinoid receptor mechanisms [4–6, 29–30], including
cyclooxygenase-2 in colorectal carcinoma cells [31]. It is
interesting to note that a recent study showed that chronic oral
administration to rats of the antiobesity drug orlistat, which is
a very potent inhibitor of 2-AG biosynthesis [32], causes
increased formation of ACF in rats [33]. This finding might be
interpreted in the light of our present results, by hypothesizing
that orlistat, by inhibiting 2-AG formation in the rat colon,
might counteract the protection against ACF formation
exerted by this endocannabinoid. We did not test the
involvement of TRPV1 receptors, which have been proposed
as an alternative target for anandamide in the gut under
pathological conditions [34], because we found a significant
increase only in the levels of 2-AG, which, in contrast to
anandamide, does not activate TRPV1 receptors [5, 6].
Caspases, a group of cysteine proteases, play an essential
role in programmed cell death [35, 36]. They convey the
apoptotic signal in a proteolytic cascade, by cleaving and
activating other enzymes that subsequently degrade cellular
targets that lead to cell death. The initiator caspases include
caspase-8 and caspase-9 [35, 36]. Caspase-8 is activated in
response to receptors with a death domain that interacts
with the fas-associated death domain (extrinsic pathway),
whereas the activation of caspase-9 is a consequence of
cytochrome c and apoptosis-activating factor 1 interaction
with AP-1 (intrinsic pathway) [35, 36]. Both initiators lead
to the activation of the final effector caspase-3, which
cleaves and inactivates several vital cellular proteins (e.g.,
DNA repair enzymes) involved in cancer cell life [35, 36].
It has been experimentally demonstrated that during
colorectal cancer formation, there is an increased cell
proliferation correlated with a reduction in apoposis [37].
In agreement with a reduction in apoptosis in colon cancer
[38], we have shown here that AOM treatment reduces the
expression of the activated caspase-3 and caspase-9 in full-
thickness colons. More importantly, treatment with the
FAAH inhibitor AA-5-HT partially reversed the AOM
effect on caspase-3, suggesting that the activation of this
caspase isoform is involved in AA-5-HT-induced inhibition
of ACF formation. Therefore, our data allow us to suggest
that whatever their exact molecular target(s), pharmacolog-
ically elevated endocannabinoids reduce ACF formation via
proapoptotic effects. It is very likely that the intrinsic
pathway is not involved in these effects, as AA-5-HT did
not affect the reduction in expression of activated caspase-9
observed in the colon of AOM-treated animals. In other
experimental studies, it has been observed that cannabinoids
induce apoptosis in other types of cancer with involvement
of extrinsic or intrinsic pathways or both [4–6, 29].
In summary, the present study provides strong evidence
that enhancement of colon endocannabinoid levels through
96 J Mol Med (2008) 86:89–98pharmacological inhibition of their enzymatic hydrolysis
may be protective against preneoplastic lesions in the
mouse colon; a condition that, like humans adenomatous
polyps and colorectal carcinoma [7], is accompanied by an
elevated endocannabinoid tone. This protective effect could
be due to indirect activation of one or more of the several
targets proposed to date for the endocannabinoids and
appears to involve caspase-3 activation and subsequent
apoptosis of colon preneoplastic cells. Further studies will
be required to investigate if cannabinoid CB2 receptors are
involved in the protective effects of AA-5-HT and HU210
and if these effects have any therapeutic relevance for the
treatment of human colon carcinoma.
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